December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

61.73 -1.81 (-2.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Potential Takeover In Works for Cardiovascular Treatment Focused Cytokinetics ↗
Cytokinetics Inc (NASDAQ: CYTK), a late-stage biotech company focused on cardiovascular treatments, is reportedly exploring potential takeover options as it has garnered interest from at least one... 
Via Benzinga
News headline image
HC Wainwright & Co. Maintains Buy Rating for Cytokinetics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Union Pacific To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Expert Ratings for Cytokinetics ↗
 
Via Benzinga
News headline image
Where Cytokinetics Stands With Analysts ↗
 
Via Benzinga
News headline image
Where Cytokinetics Stands With Analysts ↗
 
Via Benzinga
News headline image
11 Analysts Have This to Say About Cytokinetics ↗
 
Via Benzinga
News headline image
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
NuScale Power, Stagwell And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Nasdaq Composite gaining around 50 points on Friday. Here are some big stocks recording gains in Friday's session. 
Via Benzinga
Topics Stocks
News headline image
What 20 Analyst Ratings Have To Say About Cytokinetics ↗
 
Via Benzinga
News headline image
18 Analysts Have This to Say About Cytokinetics ↗
 
Via Benzinga
News headline image
Cytokinetics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Analyst Ratings for Cytokinetics ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
The 3 Best Mid-Cap Stocks to Buy Now: September 2023 ↗
With the best mid-cap stocks to buy, investors get the best of both worlds: an established business but with ample room to grow. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023 ↗
 
Via Benzinga
News headline image
Analyst Expectations for Cytokinetics's Future ↗
 
Via Benzinga
News headline image
Analyst Ratings for Cytokinetics ↗
 
Via Benzinga
News headline image
FDA Rejects Cytokinetics' Heart Failure Treatment Candidate ↗
 
Via Benzinga
News headline image
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies ↗
 
Via Benzinga
News headline image
Cytokinetics Plans To Discontinue Late-Stage ALS Trial Due To Futility ↗
Cytokinetics Incorporated (NASDAQ: CYTK) announced that the Data Monitoring Committee (DMC) for COURAGE-ALS recently convened to conduct the second planned interim analysis of this Phase 3 clinical... 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2023 ↗
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
News headline image
Cytokinetics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
News headline image
Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2023 ↗
 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.